glpg-0259
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00905138)
Timeline
Indications
Mechanism of action
MAPKAPK5 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)N1C[C@@H]2C[C@H]1CN2c1ccc(Nc2ncc(-c3coc(C(N)=O)c3)n3ncnc23)cc1- Mol. weight
- 458.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095028 ↗
- ChEMBLCHEMBL3545338 ↗
Also known as
- glpg0259
- glpg-0259
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01322451 | Phase 1 | Nov 1, 2010 | Galapagos NV, SGS Life Sciences |
| NCT01211249 | Phase 2 | Oct 1, 2010 | Galapagos NV |
| NCT01024517 | Phase 1 | Nov 1, 2009 | Galapagos NV, SGS Life Sciences |
| NCT00989703 | Phase 1 | Sep 1, 2009 | Galapagos NV, SGS Life Sciences |
| NCT00905138 | Phase 1 | Mar 1, 2009 | Galapagos NV, SGS Life Sciences |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 5 | 5 | 2 | 2009 |
| SGS Life Sciences | For profit | 4 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1